Health · Healthcare & Policy · 6 hrs ago
Medicaid GLP-1 weight-loss prescriptions fell 84% in four states after coverage ended
A study published in JAMA on Nov.
16 found that weight-loss GLP-1 prescriptions fell about 84% in four states that ended Medicaid coverage for the drugs.
The comparison was with states that continued to cover the medicines.
GLP-1 drugs are medicines approved for weight loss, and Medicaid is the public health coverage program involved in the study.
The findings link the coverage changes with a sharp drop in prescriptions in those four states.
Medicaid coverage affected access to these prescriptions, according to the comparison.
The available information does not name the states or describe any next steps.
Medicaid prescriptions for GLP-1 drugs approved for weight loss fell about 84% in four states that ended coverage.
The decline was compared with states that maintained coverage.
The finding came from a study published in JAMA on Nov. 16.
- Who
- Medicaid patients seeking GLP-1 drugs approved for weight loss.
- What
- Prescriptions fell about 84% in four states that ended coverage, compared with states that maintained it.
- When
- The study was published Nov. 16; the article was published Nov. 17, 2026.
- Where
- Four states; the states are not named.
- Why
- The article links the decline to the end of Medicaid coverage for the drugs.
This story does not have two clearly opposing sides.
The study reporting the prescription decline was published in JAMA.
Becker’s Hospital Review published an article about the study.
- Prescription decline
- About 84%
- States ending coverage
- 4
- Study outlet
- JAMA
- Study publication date
- Nov. 16